3Metra M,Nodari S,Aloia A,et al.A rationale for the use ofβ-blocker as standard treatment for heart failure.Am Heart J,2000,139:511-521.
4Cowie MR,Struthers AD,Wood DA,et al.Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care.Lancet,1997,350:1349-1353.
5McKee PA,Castelli WP,McNamara PM,Kannel WB.The natural history of congestive heart failure:the Framingham study.N Engl J Med,2007,285:1441-1446.
6McMurray J,Mcdonagh T,Morrison CE,Dargie HJ.Trends in hospitalization for heart failure in Scotland 1980-1990.Eur Heart J,1993,14:1158-1162.
7Murdoch DR,Love MP,Robb SD,et al.Importance of heart failure as a cause of death.Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979-1992.Eur Heart J,2008,19:1929-1935.
8Cleland JG,Gemmell I,Khand A,Boddy A.Is the prognosis of heart failure improving? Eur J Heart Fail,1999,1:229-241.
9Mosterd A,Hoes AW,de Bruyne MC,et al.Prevalence of heart failure and left ventricular dysfunction in the geberal population.Eur Heart J,1999,20:447-455.
10McDonagh TA,Morrison CE,Lawrence A,et al.Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population.Lancet,1997,350:829-833.
二级参考文献15
1[1]Packer M.The neurohumoral hypothesis:a theory to explain the mechanism of disease progression in heart failure.J Am Coll Cardiol,1992,20:248-254
2[2]Metra M,Nodari S,Aloia A,et al.A rationale for the use of β-blocker as standard treatment for heart failure.Am Heart J,2000,139:511-521
3[3]Coh JN,Levine TB,Ohvari MT,et al.Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.N Eng J Med,1984,311:819-823
4[4]Doughty RN,Whalley GA,Gamble G,et al.On behalf of the Australia/New Zealand Heart Failure Research Collaborative Group.Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease.J Am Coll Cardiol,1997,29:1060-1066
5[5]Lechat PP,Packer M,Chalon S,et al.Clinical effects of β-adrenergic blockade in chronic heart failure:a meta-analysis of double-blind,placebo-controlled,randomised trials.Circulation,1998,98:1184-1191
6[6]MERIT-HF Study Group.Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).Lancet,1999,353:2001-2007
7[7]CIBIS-II Investigators and Committees.The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):a randomised trial.Lancet,1999,353:9-13
8[8]Packer M.On behalf of the COPERNICUS investigators.Results of the COPERNICUS Study.Data presented at the 73rd Meeting of the American Heart Association.New Orleans,2000
9[9]Parcker M,Coats AJS,Fowler MB,et al.The effect of carvedilol on morbidity and mortality in severe chronic heart failure.N Eng J Med,2001,344:1349-1355
10[10]Poole-wilson PA,Swedberg K,Gleland JG,et al.Carvedilol Or Metoprolol European Trial Investigators.Comparison of carredilol and metoprolol on clinical out in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET):randomised controlled trial.Lancet,2003,362:7-13
